Detalhe da pesquisa
1.
Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trial.
Lancet Oncol
; 25(5): 588-602, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38608691
2.
First-in-human study of the antibody DR5 agonist DS-8273a in patients with advanced solid tumors.
Invest New Drugs
; 35(3): 298-306, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28050790
3.
A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies.
Cancer
; 118(21): 5403-13, 2012 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22570147
4.
Circulating heregulin level is associated with the efficacy of patritumab combined with erlotinib in patients with non-small cell lung cancer.
Lung Cancer
; 105: 1-6, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28236978
5.
Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer.
EBioMedicine
; 2(3): 264-71, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26137564
6.
Phase I study of U3-1287, a fully human anti-HER3 monoclonal antibody, in patients with advanced solid tumors.
Clin Cancer Res
; 19(11): 3078-87, 2013 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23591447
7.
Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5).
Cancer Biother Radiopharm
; 25(1): 13-9, 2010 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-20187792